Skip to main content
. 2020 Nov 18;12(23):24033–24056. doi: 10.18632/aging.104095

Figure 5.

Figure 5

(A) mRNA expression levels of SEPP1 and myogenic markers (MyoD and MyoG) in C2C12 cells transfected with DLEU2 as detected by RT-PCR assay. (B) Proliferation of C2C12 cells following DLEU2 overexpression. (C) mRNA expression levels of SEPP1, MyoD and MyoG in C2C12 cells transfected with DLEU2 shRNA as detected by RT-PCR assay. (D) Proliferation of C2C12 cells following transfection with DLEU2 shRNA. (E) C2C12 myoblasts were treated with DLEU2 or shRNA-1/2. EDU assays demonstrated that treatment with DLEU2 reduced cell proliferation and the level of EDU-positive C2C12 cells. Quantification of relative ratio of Edu+ C2C12 cells. Data are presented as the mean ± SD (n = 3). Versus control or NC, ** p < 0.01, ***p <0.005. (F–H) Protein expression levels of SEPP1, MyoD and MyoG in C2C12 cells transfected with DLEU2 or DLEU2 shRNA as detected by western blot assay.